Intarcia raises $210M to advance once-yearly diabetes drug

11/16/2012 | American City Business Journals · Mass High Tech (Boston)

Intarcia Therapeutics raised $210 million in a preferred stock sale and private debt placement. The company will use the proceeds to initiate late-stage trials of ITCA-650, an experimental type 2 diabetes drug intended to be administered once a year. Intarcia plans to submit the drug for approval in 2015.

View Full Article in:

American City Business Journals · Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD